Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5276220
Max Phase: Preclinical
Molecular Formula: C37H62N6O7
Molecular Weight: 702.94
Associated Items:
ID: ALA5276220
Max Phase: Preclinical
Molecular Formula: C37H62N6O7
Molecular Weight: 702.94
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C
Standard InChI: InChI=1S/C37H62N6O7/c1-11-24(10)31(43-34(46)29(38)22(6)7)36(48)40-27(18-21(4)5)33(45)42-30(23(8)9)35(47)39-26(17-20(2)3)32(44)41-28(37(49)50)19-25-15-13-12-14-16-25/h12-16,20-24,26-31H,11,17-19,38H2,1-10H3,(H,39,47)(H,40,48)(H,41,44)(H,42,45)(H,43,46)(H,49,50)/t24-,26-,27-,28-,29-,30-,31-/m0/s1
Standard InChI Key: NDCVKTFJMYWCTP-AJJIMLHCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 702.94 | Molecular Weight (Monoisotopic): 702.4680 | AlogP: 2.52 | #Rotatable Bonds: 21 |
Polar Surface Area: 208.82 | Molecular Species: ACID | HBA: 7 | HBD: 7 |
#RO5 Violations: 2 | HBA (Lipinski): 13 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.91 | CX Basic pKa: 8.21 | CX LogP: 1.75 | CX LogD: 1.69 |
Aromatic Rings: 1 | Heavy Atoms: 50 | QED Weighted: 0.10 | Np Likeness Score: 0.10 |
1. Zhou J, Li Y, Huang W, Shi W, Qian H.. (2021) Source and exploration of the peptides used to construct peptide-drug conjugates., 224 [PMID:34303870] [10.1016/j.ejmech.2021.113712] |
Source(1):